1. Home
  2. BYND vs XFOR Comparison

BYND vs XFOR Comparison

Compare BYND & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Meat Inc.

BYND

Beyond Meat Inc.

HOLD

Current Price

$0.79

Market Cap

346.2M

ML Signal

HOLD

Logo X4 Pharmaceuticals Inc.

XFOR

X4 Pharmaceuticals Inc.

HOLD

Current Price

$3.73

Market Cap

276.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BYND
XFOR
Founded
2009
2014
Country
United States
United States
Employees
N/A
143
Industry
Packaged Foods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
346.2M
276.3M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BYND
XFOR
Price
$0.79
$3.73
Analyst Decision
Sell
Strong Buy
Analyst Count
7
4
Target Price
$1.70
$28.50
AVG Volume (30 Days)
30.2M
543.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
53.80
N/A
EPS
N/A
N/A
Revenue
$326,452,000.00
N/A
Revenue This Year
N/A
$1,263.94
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.17
52 Week High
$7.69
$6.63

Technical Indicators

Market Signals
Indicator
BYND
XFOR
Relative Strength Index (RSI) 48.49 56.63
Support Level $0.67 $3.52
Resistance Level $0.82 $4.09
Average True Range (ATR) 0.08 0.23
MACD 0.01 0.06
Stochastic Oscillator 28.25 83.50

Price Performance

Historical Comparison
BYND
XFOR

About BYND Beyond Meat Inc.

Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Share on Social Networks: